A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

June 30, 2014

Conditions

Carcinomatous Edema

Interventions

DRUG

OPC-41061

orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.

Trial Locations (1)

Kansai Region